NILK 3301
Alternative Names: NILK-3301Latest Information Update: 21 Jun 2023
At a glance
- Originator LamKap Bio
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD28 antigen stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 01 Jun 2023 Parmacodynamics data from preclinical trial in Solid tumours released by Light Chain Bioscience
- 14 Apr 2023 Adverse events and pharmacodynamics data from preclinical studies in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 09 Sep 2022 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 47th European Society for Medical Oncology Congress (ESMO-2022)